Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
VRTX
vs
S&P 500
VRTX
S&P 500
Over the past 12 months, VRTX has significantly outperformed S&P 500, delivering a return of +31% compared to S&P 500's +11% growth.
Stocks Performance
VRTX vs S&P 500
Performance Gap
VRTX vs S&P 500
Performance By Year
VRTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vertex Pharmaceuticals Inc
Glance View
Vertex Pharmaceuticals is a biotech company that discovers and sells prescription medicines for serious diseases. Its best-known business is cystic fibrosis treatment, where it develops drugs that help correct the underlying protein defect that causes the disease. It also works on medicines for pain, sickle cell disease, beta thalassemia, and other hard-to-treat conditions. The company makes money by selling its medicines through pharmacies and hospitals, usually after they are prescribed by doctors. Its customers are patients, healthcare providers, and payers such as insurers and government health systems. Vertex’s model is different from many drugmakers because it has built a strong position in a narrow set of diseases, especially cystic fibrosis, where its drugs treat the root cause rather than just the symptoms. Vertex’s role in the healthcare value chain is to turn advanced biology research into specialty drugs that can command premium pricing if they show clear benefit. That means the business depends heavily on drug development, regulatory approval, and long-term relationships with the medical community and payers. It is a science-driven company with a focused product strategy, not a broad seller of many common medicines.